Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOCRYST PHARMACEUTICALS INC Director's Dealing 2013

Aug 26, 2013

31868_dirs_2013-08-26_d83b3192-be9f-4884-ac4c-9d5e0a8a4e9c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2013-07-26

Reporting Person: Barnes Alane P (VP, General Counsel & Corp Sec)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 41931 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Emp. Stock Option (Right to Buy) $9.95 2016-09-18 Common Stock (10000) Direct
Emp. Stock Option (Right to Buy) $7.98 2017-05-16 Common Stock (3512) Direct
Emp. Stock Option (Right to Buy) $3.26 2018-03-14 Common Stock (6709) Direct
Emp. Stock Option (Right to Buy) $1.20 2019-03-02 Common Stock (13500) Direct
Emp. Stock Option (Right to Buy) $6.68 2020-03-01 Common Stock (42000) Direct
Emp. Stock Option (Right to Buy) $4.15 2021-03-01 Common Stock (30000) Direct
Emp. Stock Option (Right to Buy) $4.73 2022-03-01 Common Stock (50000) Direct
Emp. Stock Option (Right to Buy) $1.42 2023-01-01 Common Stock (100000) Direct

Footnotes

F1: Options become exercisable at the rate of 25% after 1 year and then 1/48 per month thereafter until fully vested and exercisable after 48 months.

F2: Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

F3: 50,000 Annual Employee Stock Options become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. 50,000 Retention Stock Options become exercisbale at the rate of 50% on each of the first and second anniversaries of the date of grant.